Stage IV Renal Cell Cancer
80
1
4
58
Key Insights
Highlights
Success Rate
79% trial completion
Published Results
33 trials with published results (41%)
Research Maturity
58 completed trials (73% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
18.8%
15 terminated out of 80 trials
79.5%
-7.0% vs benchmark
0%
0 trials in Phase 3/4
57%
33 of 58 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 58 completed trials
Clinical Trials (80)
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer